ImmunityBio (NASDAQ:IBRX) Receives Buy Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of ImmunityBio (NASDAQ:IBRX - Free Report) in a report issued on Monday,Benzinga reports. They currently have a $30.00 price target on the stock.

Separately, EF Hutton Acquisition Co. I raised shares of ImmunityBio to a "strong-buy" rating in a research report on Wednesday, October 23rd.

ImmunityBio Price Performance

ImmunityBio stock traded down $0.05 during mid-day trading on Monday, reaching $2.76. 4,832,664 shares of the company were exchanged, compared to its average volume of 4,644,185. The firm has a market cap of $1.92 billion, a PE ratio of -3.00 and a beta of 0.86. The company has a fifty day simple moving average of $4.26 and a 200-day simple moving average of $4.48. ImmunityBio has a 12 month low of $2.50 and a 12 month high of $10.53.

Hedge Funds Weigh In On ImmunityBio

A number of institutional investors have recently modified their holdings of the business. Virtu Financial LLC bought a new position in ImmunityBio in the third quarter valued at about $51,000. Barclays PLC grew its holdings in shares of ImmunityBio by 127.4% during the 3rd quarter. Barclays PLC now owns 361,036 shares of the company's stock valued at $1,344,000 after purchasing an additional 202,248 shares during the last quarter. XTX Topco Ltd increased its position in ImmunityBio by 309.4% during the 3rd quarter. XTX Topco Ltd now owns 92,910 shares of the company's stock worth $346,000 after purchasing an additional 70,215 shares in the last quarter. State Street Corp lifted its stake in ImmunityBio by 10.1% in the 3rd quarter. State Street Corp now owns 8,654,460 shares of the company's stock valued at $32,195,000 after purchasing an additional 790,408 shares during the last quarter. Finally, HighTower Advisors LLC acquired a new stake in ImmunityBio in the third quarter valued at approximately $136,000. Institutional investors and hedge funds own 8.58% of the company's stock.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.